Filing Flows › GeneDx Holdings (WGS) › R&D spending
GeneDx Holdings (WGS) R&D spending by quarter
GeneDx Holdings' R&D spending was $19.7M in Q2 2026 (second quarter 2026), -0.7% from Q1 2026. Over the last 7 quarters it ranged from $11.6M (Q4 2024) to $24.5M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $19.7M | -0.7% | +30% |
| Q1 2026 | $19.8M | -19% | +57% |
| Q4 2025 | $24.5M | +24% | +112% |
| Q3 2025 | $19.8M | +32% | — |
| Q2 2025 | $15.1M | +20% | — |
| Q1 2025 | $12.6M | +9% | — |
| Q4 2024 | $11.6M | — | — |
Q2 2026 at a glance
GeneDx Holdings, Q2 2026: revenue $114M (+11% year over year), operating margin -15.3%, net loss $17.7M, operating cash flow −$29.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is GeneDx Holdings' R&D spending?
GeneDx Holdings' R&D spending was $19.7M in Q2 2026 (second quarter 2026), -0.7% from Q1 2026.
How has GeneDx Holdings' R&D spending changed?
Over the last 7 quarters it ranged from $11.6M (Q4 2024) to $24.5M (Q4 2025).